Clinical trials: Malignant Metastatic Melanoma
Unresectable Melanoma, Metastatic Melanoma
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
- Trial name
- NCT07459543
- Testing
- Nivolumab + Relatlimab
- Where
- 11 sites in India
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
This multi-center, prospective, observational safety study will evaluate the safety and effectiveness of Zelboraf (vemurafenib) in a real world setting.
- Trial name
- NCT01990248
- Where
- 80 sites in Austria, Belgium and 8 more
- Volunteers
- 339 people
- Sponsor
- Hoffmann-La Roche
Advanced Melanoma, Metastatic Melanoma
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
This is an exploratory prospective translational multicentre study. Melanoma is the 5th most common cancer diagnosed in Ireland and its incidence among women and men is above the European average.
- Trial name
- SYS-ACT (NCT02177110)
- Where
- 6 sites in Ireland
- Volunteers
- 16 people
- Sponsor
- Cancer Trials Ireland
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized…
- Trial name
- ABSIDE (NCT01973322)
- Testing
- arm 1: DC Vaccine + RT, arm 2: DC Vaccine + IFN-alfa, arm 3: both arm 1 and 2 + RT
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Melanoma, Malignant Melanoma
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Background: This study will use cells called DMF5 to treat patients with metastatic melanoma (melanoma that has spread beyond the primary tumor site).
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental
- Trial name
- NCT00924001
- Testing
- DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Kidney Cancer
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer
This study was designed to assess the safety and efficacy of inactivated tumor cells genetically modified with the TAG-7 gene as immunotherapy for cancer.
- Trial name
- NCT04180774
- Testing
- Tag-7 gene modified inactivated tumor cells
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity in a subgroup of patients with Stage III (unresectable) or Stage IV melanoma (measurable per modified WHO criteria)…
- Trial name
- TriMix-Ipi (NCT01302496)
- Testing
- TriMix-DC and ipilimumab
- Where
- Belgium
- Volunteers
- 39 people
- Sponsor
- Bart Neyns
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04771520
- Testing
- Avapritinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Malignant Melanoma
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
This is a Phase I study looking at the combination of Valproic Acid (VPA) and Karenitecin to treat patients with metastatic malignant melanoma.
- Trial name
- NCT00358319
- Testing
- Karenitecin, Valproic Acid
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Uveal Malignant Melanoma
Liver Transplantation and Uveal Malignant Melanoma
Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival.
- Trial name
- NCT01311466
- Testing
- Liver transplantation
- Where
- Norway
- Volunteers
- 2 people
- Sponsor
- Oslo University Hospital
Metastatic Melanoma
eFLASH for Skin Lesions of Malignant Melanomas
This prospective single center phase I trials aims to assess feasibility and safety of electron FLASH RT for treatment of melanoma skin metastases.
- Trial name
- Flash-Skin I (NCT06549439)
- Testing
- Electron FLASH radiotherapy
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- University of Zurich
Gastric Adenocarcinoma, Malignant Melanoma
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
This study is a phase II study of AZD6738 in combination with durvalumab in patients with solid tumor (cohort A (N=30): GC who have failed secondary chemotherapy treatments regimen; cohort B (B=30): melanoma patients who have…
- Trial name
- NCT03780608
- Testing
- AZD6738, Durvalumab
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Samsung Medical Center
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma (Skin)
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, paclitaxel albumin-stabilized nanoparticle formulation, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00626405
- Testing
- bevacizumab, carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 259 sites in United States
- Volunteers
- 95 people
- Sponsor
- Alliance for Clinical Trials in Oncology